As of 22 Nov 2026, PulmoGate has raised $2.1M across 1 verified round on record (amounts in other currencies converted to USD); latest: 約3.3億円 seed round led by Beyond Next Ventures, announced 18 Nov 2026.
PulmoGate offers remote multidisciplinary diagnostic and treatment support services for interstitial lung diseases.
pulmogate.com名古屋HealthtechFounded 2025
13 sources · checked 1 time, last 14h ago
Source 3 reports $2.2 million; the company's release's 約3.3億円 wins.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed | $2.1M 約3.3億円 | 2026-11-18 | Beyond Next Ventures | 8 outlets. #16 in Trending |
13 sources · checked 1 time, last 14h ago [ VERIFIED · CORRECTED ] read against 4 of 13 sources
Source 3 reports $2.2 million; the company's release's 約3.3億円 wins. | ||||
PulmoGate builds remote multidisciplinary second-opinion and AI tools that help doctors and patients diagnose, treat, and rehabilitate interstitial lung disease.
Interstitial lung disease is difficult to diagnose because symptoms and imaging can resemble other conditions and many hospitals cannot assemble the pulmonologists, radiologists, and pathologists needed for multidisciplinary discussion; PulmoGate says ILD is Japan's 11th leading cause of death and that five-year survival for idiopathic pulmonary fibrosis is 32.1%. The approximately JPY 330 million seed round led by Beyond Next Ventures is intended to expand online second opinions and fund clinical validation, regulatory work, and R&D for diagnostic and treatment AI plus at-home monitoring and rehabilitation.
Checked against 10 sources yesterday
Also named as backers in company research: Teijin Pharma, Mitsubishi UFJ Capital, STATION Ai Central Japan 2-go Investment Limited Partnership, Tongali GAP Fund, ICT Startup League